Protocol Title: Phase II Trial of High Dose Lenalidomide in Patients With MDS and AML With Trilineage Dysplasia (AML-TLD).
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 21 Oct 2016
At a glance
- Drugs Lenalidomide (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- 14 Oct 2016 Planned End Date changed from 1 Mar 2015 to 1 Dec 2016.
- 14 Oct 2016 Planned primary completion date changed from 1 Mar 2015 to 1 Dec 2016.
- 08 Dec 2015 Results (n=27), presented at the 57th Annual Meeting and Exposition of the American Society of Hematology.